Research progress of bacteriophage in treatment of periprosthetic joint infection

doi:10.3877/cma.j.issn.1674-134X.2024.01.016

Abstract

Abstract:

Periprosthetic joint infection (PJI) is a serious complication after joint replacementsurgery. Drug therapy is the basis for the treatment of PJI. However, due to the barrier effect of biofilm and the existence of drug resistance mechanism, the current drug treatment effect of PJI is still not satisfactory. In recent years, bacteriophage therapy has drawn more and more attention. Its application in the treatment of PJI has gradually received attention and some new research ideas and progress have emerged. Bacteriophages are naturally occurring viruses that specifically attack and lyse bacteria. They also have a killing effect on bacteria in biofilms, and are highly specific to bacterial species without affecting human microflora. This article reviewed the research progress of bacteriophage in the treatment of PJI from the aspects of biofilm formation and drug resistance mechanism, bacteriophage biological type and its bactericidal mechanism, the diagnostic effect of bacteriophage on PJI, the advantages and limitations of bacteriophage in the treatment of PJI, and the clinical progress of phage in the treatment of PJI, in order to provide more inspiration for the treatment of PJI.

Key words: Joint prosthesis, Infections, Bacteriophages, Biofilms, Therapeutics, Review

Youhan Yang, Yinxian Wen, Liaobin Chen. Research progress of bacteriophage in treatment of periprosthetic joint infection[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(01): 125-130.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-134X.2024.01.016

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2024/V18/I01/125

References 47

[1]	Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States[J]. J Arthroplasty, 2012, 27(8 Suppl): 61－65.e1.
[2]	Dale H, Fenstad AM, Hallan G, et al. Increasing risk of prosthetic joint infection after total hip arthroplasty[J]. Acta Orthop, 2012, 83(5): 449－458.
[3]	边焱焱，程开源，常晓，等. 2011至2019年中国人工髋膝关节置换手术量的初步统计与分析[J]. 中华骨科杂志，2020, 40(21): 1453－1460.
[4]	Ferry T, Batailler C, Brosset S, et al. Medical innovations to maintain the function in patients with chronic PJI for whom explantation is not desirable: a pathophysiology-，multidisciplinary-，and experience-based approach[J/OL]. SICOT-J, 2020, 6: 26. DOI: 10.1051/sicotj/2020021.
[5]	Shoji MM, Chen AF. Biofilms in periprosthetic joint infections: areview of diagnostic modalities, current treatments, and future directions[J]. J Knee Surg, 2020, 33(2): 119－131.
[6]	Morris J, Kelly N, Elliott L, et al. Evaluation of bacteriophage anti-biofilm activity for potential control of orthopedic implant-related infections caused by Staphylococcus aureus[J]. Surg Infect, 2019, 20(1): 16－24.
[7]	Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases[J]. Nat Rev Microbiol, 2004, 2(2): 95－108.
[8]	Akanda ZZ, Taha M, Abdelbary H. Current review-The rise of bacteriophage as a unique therapeutic platform in treating peri-prosthetic joint infections[J]. J Orthop Res, 2018, 36(4): 1051－1060.
[9]	Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections[J]. Science, 1999, 284(5418): 1318－1322.
[10]	Høiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms[J]. Int J Antimicrob Agents, 2010, 35(4): 322－332.
[11]	Bjarnsholt T, Ciofu O, Molin S, et al. Applying insights from biofilm biology to drug development - can a new approach be developed？[J]. Nat Rev Drug Discov, 2013, 12(10): 791－808.
[12]	Steadman W, Chapman PR, Schuetz M, et al. Local antibiotic delivery options in prosthetic joint infection[J/OL]. Antibiotics, 2023, 12(4): 752. DOI: 10.3390/antibiotics12040752.
[13]	Kim L. Persister cells[J]. Annu Rev Microbiol, 2010, 64: 357－372.
[14]	van Belleghem JD, Manasherob R, Międzybrodzki R, et al. The rationale for using bacteriophage to treat and prevent periprosthetic joint infections[J/OL]. Front Microbiol, 2020, 11: 591021. DOI: 10.3389/fmicb.2020.591021.
[15]	Doub JB, Urish K, Chan B. Bacteriophage therapy for periprosthetic joint infections: current limitations and research needed to advance this therapeutic[J]. J Orthop Res, 2023, 41(5): 1097－1104.
[16]	Gbejuade HO, Lovering AM, Webb JC. The role of microbial biofilms in prosthetic joint infections[J]. Acta Orthop, 2015, 86(2): 147－158.
[17]	Totten KMC, Patel R. Phage activity against planktonic and biofilm Staphylococcus aureusperiprostheticjoint infection isolates[J/OL]. Antimicrob Agents Chemother, 2022, 66(1): e0187921. DOI: 10.1128/AAC.01879-21.
[18]	Botka T, Pantůček R, Mašlaňová I, et al. Lytic and genomic properties of spontaneous host-range Kayvirus mutants prove their suitability for upgrading phage therapeutics against staphylococci[J/OL]. Sci Rep, 2019, 9(1): 5475. DOI: 10.1038/s41598-019-41868-w.
[19]	van BelleghemJD, D&#x；browska K, Vaneechoutte M, et al. Interactions between bacteriophage, bacteria, and the mammalian immune system[J/OL]. Viruses, 2018, 11(1): 10. DOI: 10.3390/v11010010.
[20]	Sosa BR, Niu Y, Turajane K, et al. 2020 John Charnley Award: the antimicrobial potential of bacteriophage-derived lysin in a murine debridement, antibiotics, and implant retention model of prosthetic joint infection[J]. Bone Joint J, 2020, 102－B(7_Supple_B): 3－10.
[21]	程永帅，刘炜洁，于腾波，等. 噬菌体裂解酶对兔膝关节假体周围感染的影响[J]. 中华实验外科杂志，2018, 35(12): 2289－2291.
[22]	Gutiérrez D, Rodríguez-Rubio L, Martínez B, et al. Bacteriophages as weapons against bacterial biofilms in the food industry[J/OL]. Front Microbiol, 2016, 7: 825. DOI: 10.3389/fmicb.2016.00825.
[23]	Šuster K, Cör A. Induction of viable but non-culturable state in clinically relevant staphylococci and their detection with bacteriophage K[J/OL]. Antibiotics, 2023, 12(2): 311. DOI: 10.3390/antibiotics12020311.
[24]	Boyle KK, Wood S, Tarity TD. Low-virulence organisms and periprosthetic joint infection-biofilm considerations of these organisms[J]. Curr Rev Musculoskelet Med, 2018, 11(3): 409－419.
[25]	Šuster K, Cör A. Fast and specific detection of staphylococcal PJI with bacteriophage-based methods within 104 sonicate fluid samples[J]. J Orthop Res, 2022, 40(6): 1358－1364.
[26]	Šuster K, Podgornik A, Cör A. An alternative molecular approach for rapid and specific detection of clinically relevant bacteria causing prosthetic joint infections with bacteriophage K[J]. New Microbiol, 2020, 43(3): 107－114.
[27]	Gemmel F, van den Wyngaert H, Love C, et al. Prosthetic joint infections: radionuclide state-of-the-art imaging[J]. Eur J Nucl Med Mol Imaging, 2012, 39(5): 892－909.
[28]	Jacqueline C, Caillon J. Impact of bacterial biofilm on the treatment of prosthetic joint infections[J]. J Antimicrob Chemother, 2014，69(Suppl 1): i37－i40.
[29]	Bruttin A, Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy[J]. Antimicrob Agents Chemother, 2005, 49(7): 2874－2878.
[30]	Hadas H, Einav M, Fishov I, et al. Bacteriophage T4 development depends on the physiology of its host Escherichia coli[J]. Microbiology, 1997，143( Pt 1): 179－185.
[31]	Pearl S, Gabay C, Kishony R, et al. Nongenetic individuality in the host-phage interaction[J/OL]. PLoS Biol, 2008, 6(5): e120. DOI: 10.1371/journal.pbio.0060120.
[32]	Wright A, Hawkins CH, Anggård EE, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy[J]. Clin Otolaryngol, 2009, 34(4): 349－357.
[33]	Ferry T, Leboucher G, Fevre C, et al. Salvage debridement, antibiotics and implant retention ( "DAIR" ) with local injection of a selected cocktail of bacteriophages: is it an option for an elderly patient with relapsing Staphylococcus aureusprosthetic-joint infection？[J/OL]. Open Forum Infect Dis, 2018, 5(11): ofy269. DOI: 10.1093/ofid/ofy269.
[34]	李朔，徐一宏，徐卫东. 人工关节置换术后感染的生物治疗方法及前景[J/CD]. 中华关节外科杂志(电子版), 2019, 13(2): 213－219.
[35]	van Belkum A, Gros MF, Ferry T, et al. Novel strategies to diagnose prosthetic or native bone and joint infections[J]. Expert Rev Anti Infect Ther, 2022, 20(3): 391－405.
[36]	DePalma BJ, Nandi S, Chaudhry W, et al. Assessment of staphylococcal clinical isolates from periprosthetic joint infections for potential bacteriophage therapy[J]. J Bone Joint Surg Am, 2022, 104(8): 693－699.
[37]	Donlan RM. Preventing biofilms of clinically relevant organisms using bacteriophage[J]. Trends Microbiol, 2009, 17(2): 66－72.
[38]	Łusiak-Szelachowska M, Zaczek M, Weber-Dąbrowska B, et al. Phage neutralization by sera of patients receiving phage therapy[J]. Viral Immunol, 2014, 27(6): 295－304.
[39]	Cano EJ, Caflisch KM, Bollyky PL, et al. Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniaeinfection: case report and in vitrocharacterization of anti-biofilm activity[J/OL]. Clin Infect Dis, 2021, 73(1): e144－e151. DOI: 10.1093/cid/ciaa705.
[40]	Insall JN, Thompson FM, Brause BD. Two-stage reimplantation for the salvage of infected total knee arthroplasty. 1983[J/OL]. J Bone Joint Surg Am, 2002, 84(3): 490. DOI: 10.2106/00004623-200203000-00024.
[41]	Fedorov E, Samokhin A, Kozlova Y, et al. Short-term outcomes of phage-antibiotic combination treatment in adult patients with periprosthetic hip joint infection[J/OL]. Viruses, 2023, 15(2): 499. DOI: 10.3390/v15020499.
[42]	Ferry T, Kolenda C, Batailler C, et al. Case report: arthroscopic "debridement antibiotics and implant retention" with local injection of personalized phage therapy to salvage a relapsing Pseudomonas aeruginosaprostheticknee infection[J/OL]. Front Med, 2021, 8: 569159. DOI: 10.3389/fmed.2021.569159.
[43]	Cesta N, Pini M, Mulas T, et al. Application of phage therapy in a case of a chronic hip-prosthetic joint infection due to Pseudomonas aeruginosa: an Italian real-life experience and in vitroanalysis[J/OL]. Open Forum Infect Dis, 2023, 10(2): ofad051. DOI: 10.1093/ofid/ofad051.
[44]	Ferry T, Kolenda C, Gustave CA, et al. Phage therapy in bone and joint infection: history, scientific basis, feasibility and perspectives in France[J]. Virologie, 2020, 24(1): 49－56.
[45]	Taha M, Abdelbary H, Ross FP, et al. Newinnovations in the treatment of PJI and biofilms-clinical and preclinical topics[J]. Curr Rev Musculoskelet Med, 2018, 11(3): 380－388.
[46]	Morris JL, Letson HL, Elliott L, et al. Evaluation of bacteriophage as an adjunct therapy for treatment of peri-prosthetic joint infection caused by Staphylococcus aureus[J/OL]. PLoS One, 2019, 14(12): e0226574. DOI: 10.1371/journal.pone.0226574.
[47]	Kaur S, Harjai K, Chhibber S. In vivoassessment of phage and linezolid basedimplant coatings for treatment of methicillin resistant S. aureus (MRSA) mediated orthopaedicdevice related infections[J/OL]. PLoS One, 2016, 11(6): e0157626. DOI: 10.1371/journal.pone.0157626.

Please choose a citation manager

Content to export